Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PollenVax in Mugwort Pollen-Induced Allergic Rhinitis
NCT07317960Phase 1Completed
- Sponsor
- Kazakh National Agrarian Research University
- Start
- Nov 2025
- Primary completion
- Jan 2026
- Modality
- Allergy Immunotherapy
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in allergic rhinitis (AR) comparing PollenVax with Placebo Comparator (2 arms). Primary endpoints: Safety and tolerability of PollenVax and Frequency and pattern of adverse events. Started Nov 2025; status: completed.
02
Drugs
artemisia pollen allergen extract
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT07317960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07317960.